Quantcast

Latest ERBB Stories

2011-04-20 08:59:00

CAMBRIDGE, Mass., April 20, 2011 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. announced today that five patients have received therapy in a Phase I clinical study combining MM-111 with multiple standard treatment regimens for patients with advanced HER2 positive (HER2+) solid tumors. (Logo: http://photos.prnewswire.com/prnh/20100913/NE63515LOGO ) MM-111 is a bi-specific antibody that targets tumor cells over-expressing ErbB2/HER2. MM-111 is designed to inhibit the signaling between...

4eed36960aad25c3ea887154094418b61
2010-12-23 08:02:49

Implications for blocking metastasis and improving responses to existing therapies Overexpression or hyperactivation of ErbB cell-surface receptors drives the growth of many breast cancers. Drugs, like Herceptin, that block the receptors' signals halt tumor progression in some patients. However, not all patients' tumors respond, with some becoming resistant over time. Different drugs that interfere with other steps in the signaling pathway may improve the response of patients, yet little is...

2010-10-27 10:38:00

PRINCETON, N.J., Oct. 27 /PRNewswire/ -- Laureate Pharma, Inc., a full-service contract development and manufacturing organization, announced today that they have entered into a development and manufacturing agreement to produce AV-203, AVEO Pharmaceutical's (Cambridge, MA) novel monoclonal antibody targeted against ErbB3. Laureate's services will include process development, protein production, purification and aseptic filling of AP-203 for AVEO. The project is presently underway and...

2010-07-22 06:00:00

CAMBRIDGE, Mass., July 22 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. and sanofi-aventis announced today that the first patient has received an initial dose in a Phase 2 randomized double blind clinical study combining MM-121 with exemestane (Aromasin®) in breast cancer patients. MM-121, Merrimack's lead oncology therapeutic candidate, is an antibody designed to block signaling of ErbB3. ErbB3 is a key mediator of the ErbB pathway, a pathway...

2010-06-04 14:18:31

MM-111 antibody uses HER2 target to reach and block HER3 Patients with HER2-positive cancers can have dramatic responses to HER2-targeted drugs but eventually develop resistance to the agents. With that problem in mind, Fox Chase Cancer Center researchers are testing a novel type of antibody called MM-111 in patients with HER2-positive disease who have progressed on standard therapy. Unlike natural antibodies, which have two arms that recognize the same antigen, the new MM-111 antibody has...

2010-04-30 13:34:00

CAMBRIDGE, Mass., April 30 /PRNewswire/ -- Merrimack Pharmaceuticals' MM-111 Team Leader Charlotte McDonagh, Ph.D., will discuss the development of this novel, bispecific antibody on Tuesday, May 4, at the BIO 2010 International Convention in Chicago, Illinois. Designed to specifically inhibit ErbB3 signaling in ErbB2 over-expressing cancer cells, MM-111 binds to the critical ErbB2/ErbB3 cell receptor signaling complex and disables it from activating the phosphatidylinositol 3-kinase...

2010-02-22 06:00:00

CAMBRIDGE, Mass., Feb. 22 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. announced today that the first patient has received an initial dose in a Phase 1/2 clinical study combining MM-121 with Tarceva(®) (erlotinib) in patients with non-small cell lung cancer (NSCLC). This is the first of multiple trials that Merrimack and sanofi-aventis expect to initiate in 2010 as part of a broad Phase 2 clinical development program for MM-121. MM-121, Merrimack's lead oncology...

2008-12-12 11:00:00

- Global Phase 3 Program Expected to Begin in December - COLLEGEVILLE, Pa., Dec. 12 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced data from an open-label phase 2 clinical trial of neratinib (HKI-272) in women with advanced HER-2-positive breast cancer. These data suggest that neratinib has antitumor activity in patients with advanced breast cancer positive for the ErbB-2 receptor (also known as HER-2 or Neu). These data were presented...

2008-08-14 03:00:47

Merrimack Pharmaceuticals has announced that the first patient has received an initial dose in a Phase I clinical study of the company's first oncology product, MM-121, a fully human monoclonal antibody and a therapeutic designed to block signaling of the ErbB3 receptor. ErbB3 is a receptor in the ErbB family, a pathway that plays a critical role in cancer signaling. With the initiation of the Phase I trial, MM-121 becomes the first systems biology product as well as the first selective...

2008-08-11 09:00:21

CAMBRIDGE, Mass., Aug. 11 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. today announced that the first patient has received an initial dose in a Phase 1 clinical study of the Company's first oncology product, MM-121, a fully human monoclonal antibody and a first-in-class therapeutic designed to block signaling of the ErbB3 receptor. ErbB3 is a receptor in the ErbB family, a pathway that plays a critical role in cancer signaling. With the initiation of the Phase 1 trial, MM-121 becomes...


Word of the Day
mundungus
  • A stinking tobacco.
  • Offal; waste animal product; organic matter unfit for consumption.
This word comes from the Spanish 'mondongo,' tripe, entrails.